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Up-regulation of lipogenesis by androgen is one of the most
characteristic metabolic features of LNCaP prostate cancer cells.
The present study revealed that androgen increases glucose
utilization for de novo lipogenesis in LNCaP cells through
the activation of HK2 (hexokinase 2) and activation of the
cardiac isoform of PFKFB2 (6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase). Activation of PKA (cAMP-dependent
protein kinase) by androgen increased phosphorylation of CREB
[CRE (cAMP-response element)-binding protein], which in turn
bound to CRE on the promoter of the HK2 gene resulting
in transcriptional activation of the HK2 gene. Up-regulation
of PFKFB2 expression was mediated by the direct binding of
ligand-activated androgen receptor to the PFKFB2 promoter.
The activated PI3K (phosphoinositide 3-kinase)/Akt signalling
pathway in LNCaP cells contributes to the phosphorylation of
PFKFB2 at Ser466 and Ser483, resulting in the constitutive activation
of PFK-2 (6-phosphofructo-2-kinase) activity. Glucose uptake
and lipogenesis were severely blocked by knocking-down of
PFKFB2 using siRNA (small interfering RNA) or by inhibition
of PFK-2 activity with LY294002 treatment. Taken together,
our results suggest that the induction of de novo lipid synthesis
by androgen requires the transcriptional up-regulation of HK2
and PFKFB2, and phosphorylation of PFKFB2 generated by the
PI3K/Akt signalling pathway to supply the source for lipogenesis
from glucose in prostate cancer cells.
Key words: androgen, glycolysis, hexokinase 2, 6-phos-
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INTRODUCTION
Prostate cancer is the most common cancer in males, where
androgen is a critical factor in regulating cell proliferation and
growth. The most characteristic metabolic change by androgen in
prostate cancer cells is the induction of de novo lipid synthesis
through the up-regulation of lipogenic enzyme expression [1–5].
Since the metabolites from glycolysis are the main carbon sources
for lipid synthesis, glycolysis should be controlled along with
lipogenesis. Although the function of androgen in lipogenesis
has been extensively investigated, little is known about the role
of androgen in glycolysis for de novo lipid synthesis. In the
present study, we carried out a set of experiments to elucidate
the mechanism by which androgen controls glycolysis for support
of vigorous lipogenesis in LNCaP prostate cancer cells.
A critical step for a high glycolytic state is the phosphorylation
of glucose, which is catalysed by HK (hexokinase) [6,7]. Among
the four mammalian HK types (HK 1–4), HK2 is frequently the
predominant overexpressed form in tumours [8–10]. Furthermore,
mounting evidence indicates that HK2 plays a pivotal role
in highly malignant cancer cells by promoting cell growth,
survival, enhancing biosynthesis and helping immortalization of
the cells under hypoxic conditions. Another key step in controlling
the glycolytic flux is the conversion of Fru-6-P (fructose 6-
phosphate) into Fru-1,6-P2 (fructose 1,6-bisphosphate) by PFK-1
(phosphofructokinase). The activity of PFK-1 is allosterically
controlled by Fru-2,6-P2 (fructose 2,6-bisphosphate), which
is produced by the bifunctional PFKFB (6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase), which catalyses both the
biosynthesis and degradation of Fru-2,6-P2 [11]. In mammals, the
isoforms of PFKFB are encoded by four separate genes (PFKFB1,
PFKFB2, PFKFB3 and PFKFB4), which are characterized by
tissue expression pattern, the ratio of kinase to phosphatase
activity, and the response to protein kinases [12]. In cancer
cells, the level of Fru-2,6-P2 is generally elevated [11,13,14] due
to overexpression and the activation of PFKFB3 and PFKFB4
[15,16]. PFKFB2, the cardiac isoform of PFKFB, is an essential
enzyme in the regulation of glycolysis in the heart. Adrenaline,
insulin and a work load increase the level of Fru-2,6-P2 by
elevated PFK-2 (6-phosphofructo-2-kinase) activity of PFKFB2
[17–19]. The C-terminal regulatory domain of PFKFB2, which
is absent in the liver isoform PFKFB1, can be phosphorylated on
both Ser466 and Ser483 by PDK-1 (3-phosphoinositide-dependent
kinase-1), PKA (cAMP-dependent protein kinase), p70S6K
(p70 ribosomal S6 kinase) and MAPK-1 (mitogen-activated
protein kinase-1) [19,20]. These findings suggest that increased
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Fru-2,6-P2 production by elevated PFK-2 activity of PFKFB2 may
play an important role in transformation of non-malignant cells
or proliferation of cancer cells.
In the present study, we demonstrate that androgen up-regulates
the expression of HK2 and PFKFB2, resulting in elevation
of the utilization of glucose for de novo lipid synthesis in LNCaP
prostate cancer cells. We show that androgen-induced HK2
expression is dependent on PKA signalling, and the induction
of PFKFB2 expression is achieved by a direct binding of
the androgen receptor to the PFKFB2 promoter. Constitutive
activation of the PI3K (phosphoinositide 3-kinase)/Akt signalling
pathway in LNCaP cells plays a critical role in the activation of
PFK-2 activity of PFKFB2. In conclusion, these results suggest
that androgen stimulates the utilization of glucose to undergo a
metabolic conversion for both production of ATP and lipogenesis
in androgen-dependent prostate cancer cells.
MATERIALS AND METHODS
Reagents
R1881 (methyltrienolone), a synthetic androgen, was purchased
from Dupont-New England Nuclear and dissolved in DMSO.
Forskolin, H-89 and LY294002 were purchased from Sigma–
Aldrich and dissolved in DMSO.
Cell culture and routine procedures
Details of cell culture condition and routine procedures,
including transfection, reporter assays, construction of plasmids,
quantitative RT-PCR (real-time PCR), Western blotting and
ChIP (chromatin immunoprecipitation) assays, are described in
the Supplementary Materials and methods section (at http://
www.BiochemJ.org/bj/433/bj4330225add.htm).
RNAi (RNA interference)
siRNA (small interfering RNA) oligonucleotides targeting
PFKFB2 and control siRNA were purchased from Shanghai Ge-
nepharma. The siRNA oligonucleotide sequences were: PFKFB2
#1, 5′-AGAGCAAGAUAGUCUACUATT-3′; PFKFB2 #2, 5′-
AGGAAAUAACAGACCUCAATT-3′; PFKFB2 #3, 5′-GUGG-
AAACAAUUAAACUUATT-3′; and control siRNA, 5′-UUCUC-
CGAACGUGUCACGUTT-3′. Transfections were performed
twice over 2 days using LipofectamineTM RNAiMAX (Invitrogen)
according to the manufacturer’s instructions. Details of RNAi are
shown in the Supplementary Materials and methods section.
PFK-2 activity assay
PFK-2 activity was measured according to the method
described by Manzano et al. [23]. Briefly, cleared cell lysates
were obtained by homogenization in 500 μl of buffer A
[50 mM Tris/HCl (pH 7.4), 0.1 M KCl, 0.5 mM EDTA, 5 mM
MgCl2, 50 mM potassium fluoride, 1 mM DTT (dithiothreitol),
10 mg/ml leupeptin, 10 mg/ml aprotinin and 0.5 mM PMSF],
and centrifuged at 13000 g at 4 ◦C for 10 min. Supernatants
were mixed with 1 vol. of buffer B [100 mM Tris/HCl (pH 7.1),
200 mM KCl, 10 mM ATP, 4 mM MgCl2, 2 mM KH2PO4,
10 mM Fru-6-P, 35 mM glucose 6-phosphate and 2 mM DTT]
and incubated at 30 ◦C for 30 min. Reactions (200 μl volume)
were stopped by the addition of 1 vol. of 0.2 M NaOH
followed by heating at 80 ◦C for 10 min, then neutralized with
40 μl of ice-cold 1 M acetic acid in 20 mM Hepes. After
centrifugation (13000 g for 10 min at 4 ◦C), 350 μl aliquots of
supernatant was mixed with 500 μl of reaction mixture [100 mM
Figure 1 Androgen increases glucose uptake and lipid synthesis in LNCaP
cells
Glucose uptake (A), lactate production (B) and lipid synthesis from D-[1-14C]glucose (C) were
measured in LNCaP cells in the absence or the presence of 10 nM R1881 for 72 h. Results
shown are the means +− S.D. of triplicate samples from a representative experiment. (D) In each
group, the amount of FASN, ACLY and ACACA were measured by Western blot analysis, using
tubulin as an internal control. (E) Quantitative RT-PCR analysis was performed to measure the
level of mRNAs for HK2 and PFKFB isoforms in LNCaP cells in the absence (open columns)
or the presence (solid columns) of 10 nM R1881 for 72 h. Relative amounts of mRNAs were
represented using GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA as an invariant
control. *P < 0.05. EtOH, ethanol.
Tris/HCl (pH 8.0), 4 mM magnesium acetate, 2 mM Fru-6-P and
0.3 mM NADH], and then the mixtures were incubated with
100 μl of enzyme stock solution [1 unit/ml PPi-PFK (Fru-6-P
1-phosphotransferase), 500 units/ml triosephosphate isomerase,
170 units/ml α-glycerophosphate dehydrogenase and 45 units/ml
aldolase] at 25 ◦C for 5 min. All enzymes were purchased from
Sigma–Aldrich. The assay was started by the addition of 50 μl of
10 mM PPi solution in the mixtures. Absorbance at 340 nm was
measured at room temperature (25 ◦C) every 1 min for a period
of 10 min with an Ultrospec 1100 pro-spectrometer as described
previously [22,23]. Assays were performed in triplicate.
Glucose uptake and lactate assay
LNCaP cells (6 × 105 cells/well) or PC3 cells (2×105 cells/well)
were plated on six-well plates and treated as indicated. For the
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Figure 2 Androgen activates the transcription of the HK2 gene via cAMP/PKA signalling in LNCaP cells
(A) The luciferase activity of the HK2 promoter was measured in LNCaP cells transfected with the pHK2-Luc construct, after incubation for 72 h in the absence or the presence of 10 nM R1881.
At 24 h before harvest, when used, H-89 was added at a final concentration of 10 μM. Luciferase activities were normalized to the activities of SV40 (simian virus 40) promoter-driven Renilla
luciferase. Values are the means +− S.D. of triplicate samples from a representative experiment. *P < 0.05. (B) The levels of HK2 were analysed by Western blot analysis with the protein extracts
of LNCaP cells treated as described in (A). Tubulin was used as an invariant control. (C) The conserved CRE in the HK2 promoter located at –504 from the ATG codon was mutated as shown.
LNCaP cells transfected with promoter–Luc constructs harbouring wild-type or mutant CRE were incubated in the absence (open column) or the presence (solid column) of 10 nM R1881 for
72 h. Values are the means +− S.D. of triplicate samples from a representative experiment. (D) PKA activities were measured as described in Supplementary Materials and methods section (at
http://www.BiochemJ.org/bj/433/bj4330225add.htm) in LNCaP cells treated as described in (A). Data shown are relative to that of the group not treated with R1881. (E) In each group, the levels of
PKA-Cβ2, phospho-CREB and total CREB in nuclear fractions were measured by Western blot analyses. (F) The activities of the HK2 promoter were assayed in PC3 cells exogenously overexpressing
PKA-Cβ2. Cells were transfected with the pHK2-Luc construct in combination with the empty vector or pSG5-PKA-Cβ2. The relative luciferase activities were analysed 48 h after transfection. Values
are the means +− S.D. of triplicate samples from a representative experiment. EtOH, ethanol.
glucose-uptake assay, cells were incubated in glucose-free RPMI
1640 medium (Invitrogen) for 6 h, then supplied with approx. 0.3
MBq (10 μCi) [18F]FDG ([18F]fluoro-2-deoxyglucose) per well.
After incubation at 37 ◦C for 20 min, cells were washed twice with
PBS. The cells were harvested in PBS, and the radioactivity was
measured using a Wallac 148 Wizard 3 γ -counter (PerkinElmer
Life and Analytical Science). All experiments were performed
in triplicate. The lactate levels in the culture medium were
measured using a lactate assay kit according to the manufacturer’s
instructions (Biovision).
Lipid synthesis assay
Lipid synthesis from glucose was assayed by measuring the
incorporation of 14C from D-[1-14C]glucose (PerkinElmer Life
and Analytical Science) into lipid. Cells in six-well plates were
incubated for 6 h in glucose-free RPMI 1640 medium and then
were treated with 72 μM of D-[1-14C]glucose (4 μCi/ml) for
2 h. Cells were harvested and washed three times with PBS, and
disrupted by adding 400 μl of 0.5% Triton X-100. The lipids
were extracted with 500 μl of a hexane/isopropanol solution [3:2
(v:v)]. Aliquots of solvent layer were collected and dried under
nitrogen gas. The dried samples were resuspended in 50 μl of
chloroform, and the radioactivity of 14C was counted on a LS
6500 scintillation counter (Beckman Coulter).
Statistical analysis
SPSS for Windows version 17.0 was used for all statistical
analyses.
RESULTS
Androgen activates glycolysis and lipid synthesis in LNCaP cells
To observe the changes in glycolysis by androgen in androgen-
dependent LNCaP prostate cancer cells, glucose uptake and
lactate production were measured after treatment with R1881, an
androgen agonist. The uptake of [18F]FDG, which accumulates as
2-deoxyglucose 6-phosphate, over 20 min was markedly elevated
up to 3-fold in cells treated with R1881 (Figure 1A), whereas
lactate production was remained unchanged (Figure 1B). To
determine whether the increase in glucose uptake serves as
a substrate for the synthesis of lipids in LNCaP cells, we
measured the amount of hexane/isopropanol-extractable lipids
synthesized with D-[1-14C]glucose. R1881 drastically increased
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Figure 3 Androgen increases the expression of PFKFB2 in LNCaP cells by recruiting liganded androgen receptor to the PFKFB2 promoter
(A) The relative amounts of mRNA for PFKFB2 and KLK3 were determined by quantitative RT-PCR in a time course after treatment with 10 nM R1881. Each amount of mRNA was normalized
using GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA as an invariant control. (B) The levels of protein for PFKFB2 were measured by Western blot analysis in the extracts of
LNCaP cells treated with R1881 for the indicated times. Tubulin was used as an invariant control. (C) ChIP analyses were performed on LNCaP cells treated with 10 nM R1881 for 6 h using an
androgen-receptor(AR)-specific antibody or non-specific IgG. The indicated chromosomal regions, denoted as nucleotide numbers from the transcription start of the PFKFB2 gene, were amplified
by PCR and analysed in 1.2 % agarose-gel electrophoresis. EtOH, ethanol; IP, immunoprecipitation.
the incorporation of 14C from glucose into lipids up to 7-fold
(Figure 1C), and this result was supported by marked induction of
lipogenic enzymes, such as FASN (fatty acid synthase), ACLY
(ATP citrate lyase) and ACACA (acetyl-CoA carboxylase α)
(Figure 1D). These results suggest that the androgen-dependent
activation of glucose uptake provides an important carbon source
for androgen-dependent lipogenesis.
Androgen induces the expression of HK2 and PFPKB2 in LNCaP
cells
On the basis of the assumption that the increase in glycolysis
supports androgen-dependent lipogenesis, microarray analyses
were carried out to reveal glycolytic genes whose expression
is under the control of androgen. The expression of HK2 and
PFKFB2 genes were increased 2.6- and 3.0-fold by R1881
treatment. Quantitative RT-PCR confirmed these significant
increases in HK2 and PFKFB2, whereas other PFKFB isoforms
remained unchanged (Figure 1E). These results indicate that HK2
and PFKFB2 could have an important role in the androgen-
dependent increase in glycolysis in LNCaP cells.
PKA signalling activated by androgen stimulates the expression of
HK2
CREB [CRE (cAMP-response element)-binding protein] plays
a critical role in the strong transcriptional activation of
the HK2 promoter, which contains a well-characterized CRE
[24–26]. CREB is the transcriptional activator associated with the
cAMP/PKA signalling pathway, which is stimulated in LNCaP
cells after androgen treatment [26a]. On the basis of these previous
observations, we examined whether the induction of HK2 by
androgen in LNCaP cells is achieved by transcriptional activation
of the HK2 promoter (–2054/+21) via the cAMP/PKA signalling
pathway. The activity of the HK2 promoter was increased
8-fold by androgen and this activation was significantly attenuated
by treatment with H-89, an inhibitor of PKA (Figure 2A).
Consistent with the HK2 promoter activity, the HK2 protein
level was markedly increased by androgen. However, whereas
H-89 only partially inhibited luciferase activity (Figure 2A), it
fully blocked the induction of protein accumulation (Figure 2B).
The difference between the HK2 protein mass and luciferase
activity might be due to different stabilities of these proteins
in cells treated with H-89. To determine whether androgen-
mediated activation of the HK2 promoter is dependent on CRE,
the CRE was mutated as shown in Figure 2(C). Mutation of CRE
completely suppressed the responsiveness to androgen, indicating
that CRE plays a critical role in the regulation of the HK2
promoter by androgen (Figure 2C). We have shown previously
that androgen induces PKA activity by increasing the expression
of PKA-Cβ2 (PKA catalytic subunit β transcript variant 2) in
LNCaP cells [26a]. In the present study, we confirmed that PKA
activity, the PKA-Cβ2 protein level and phosphorylation of CREB
were significantly increased by R1881 treatment in LNCaP cells
(Figures 2D and 2E). Exogenous overexpression of PKA-Cβ2
markedly activated the HK2 promoter in PC3 cells (Figure 2F).
These results suggest that the induction of HK2 expression
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by androgen in LNCaP cells resulted from activation of PKA
signalling.
Androgen induces the recruitment of androgen receptors to the
PFKFB2 promoter resulting in induction of PFKFB2
To determine whether PFKFB2 is a direct target gene of the
androgen receptor, we compared the regulation of PFKFB2 with
the KLK3 (kallikrein-related peptidase 3) gene, which is a known
target of the androgen receptor in LNCaP cells. As shown in
Figure 3(A), both KLK3 and PFKFB2 mRNA accumulated in a
similar manner by treatment with R1881. PFKFB2 mRNA was
significantly induced after treatment with R1881 by 1.8- and 2.5-
fold at 6 and 12 h respectively. The amount of KLK3 mRNA
was increased to a slightly higher level by 2.7- and 7-fold at 6
and 12 h respectively (Figure 3A). In accordance with the mRNA
data, PFKFB2 protein was markedly increased 24 h after R1881
treatment and continued to increase until 72 h (Figure 3B). To
elucidate whether the androgen receptor directly binds to the
PFKFB2 promoter, a ChIP assay was carried out in LNCaP
cells 6 h after R1881 treatment using an antibody against the
androgen receptor. Five regions located at approx. 1 kb intervals
on the PFKFB2 promoter were amplified by PCR using chromatin
immunoprecipitates as templates (Figure 3C). Treatment with
R1881 increased the recruitment of the androgen receptor only
on the –1361 to –1077 region from the transcription start site
(GenBank® accession number NM_006212.2), suggesting that a
functional ARE (androgen-response element) is located at this
region and is involved in the androgen-mediated regulation of
PFKFB2 expression.
Next, we examined the effects of androgen on PFKFB2
promoter activity, using a pPFKFB2–Luc construct which
contains the PFKFB2 promoter fragment (–1949/+92)
complexed with the luciferase gene. Androgen increased the
luciferase activity by 3-fold (Figure 4A), which correlates
with the androgen-induced increase in endogenous PFKFB2
gene expression. In order to find the key sequence element
involved in androgen-mediated regulation, the putative ARE in the
PFKFB2 promoter was searched using the MatInspector program
of Genomatix software (http://www.genomatix.de). Only one
putative ARE was found at –1204 and its mutation resulted in
complete unresponsiveness to R1881 (Figure 4B), suggesting that
the ARE at –1204 mediates the androgen-dependent activation
of the PFKFB2 promoter. Taken together, these results indicate
that the PFKFB2 gene is a direct binding target of the androgen
receptor and is activated by androgen in the LNCaP cells.
PI3K/Akt signalling is involved in the phosphorylation of PFKFB2 in
LNCaP cells
The unique C-terminal region of PFKFB2, which is not conserved
in the other isoforms of PFKFB, contains the critical residues
(Ser466 and Ser483) that control the enzyme activity through
their phosphorylation status [17,19,20,27]. R1881 increased the
phosphorylation at Ser466 and Ser483 of PFKFB2 as well as
increasing the total enzyme level (Figure 5A). To determine
the signalling pathway involved in the phosphorylation of
these residues, LNCaP cells were treated with forskolin (a
PKA activator), H-89 (a PKA inhibitor) or LY294002 (a PI3K
inhibitor) for 40 min after treatment with R1881 for 72 h. The
level of phosphorylation at Ser466 and Ser483 was not affected
by treatment with forskolin or H-89 (Figure 5B), whereas
LY294002 significantly decreased the phosphorylation of both
Ser466 and Ser483 (Figure 5C). Consistent with this decreased level
Figure 4 Androgen activates the PFKFB2 promoter in LNCaP cells
(A) LNCaP cells were transfected with the pPFKFB2–Luc construct, then incubated for 72 h in
the absence or the presence of 10 nM R1881. The relative luciferase activities were analysed
as described in Figure 1(A). Data shown are the means +− S.D. of triplicate samples from a
representative experiment. (B) A putative consensus ARE is underlined in the PFKFB2 promoter,
and the mutant construct was generated by the destruction of this consensus as indicated by
lowercase characters. The responsiveness to R1881 was measured in LNCaP cells transfected
with the wild-type pPFKFB2–Luc construct or the mutant construct as described in (A). Data
shown are the means +− S.D. of triplicate samples from a representative experiment. EtOH,
ethanol.
of phosphorylation, LY294002 markedly inhibited the PFK-2
activity (Figure 5D) and glucose uptake (Figure 5E) was increased
by R1881. In LNCaP cells, it has been reported that the PI3K/Akt
signalling pathway is constitutively activated by mutations in
the PTEN (phosphatase and tensin homologue) gene and is
likely to participate in activation of PFK-2 activity. Inhibition of
glucose uptake by LY294002 resulted in the block of the flux
of carbon from [14C]glucose into lipid synthesis (Figure 5F)
without significant changes in amounts of lipogenic enzymes and
the androgen receptor (Figure 5G). These results suggest that the
PFK-2 activity of the bifunctional enzyme PFKFB2 should be
activated by PI3K/Akt signalling for the high rate of glycolysis to
support androgen-induced lipogenesis.
PFKFB2 has a critical role in glucose uptake and
glucose-dependent lipid synthesis
Inhibition of the PI3K/Akt signalling pathway drastically
decreased PFK-2 activities and glucose uptake. Because the
PI3K/Akt signalling pathway affects diverse metabolic pathways,
the direct contribution of the PFK-2 activity of PFKFB2 to glucose
uptake should be confirmed. Overexpression of PFKFB2 by
c© The Authors Journal compilation c© 2011 Biochemical Society
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Figure 5 The PI3K signalling pathway is involved in the phosphorylation of Ser466 and Ser483 of PFKFB2
(A) The amount of total or phosphorylated forms of PFKFB2 (Ser466 and Ser483) were measured by Western blot analyses in LNCaP cells treated with 10 nM R1881 for the times indicated. (B and C)
LNCaP cells grown in medium containing 10 nM R1881 for 72 h were treated with 10 μM forskolin or H-89 (B) or with 25 μM LY294002 for 40 min before harvest (C). The amounts of indicated
proteins were determined by Western blot analyses using tubulin as an invariant control. (D–G) LNCaP cells were grown in the absence or the presence of 10 nM R1881 for 72 h, then treated with
25 μM LY294002 for 40 min before harvest. PFK-2 activity (D), glucose uptake (E) and lipid synthesis from D-[1-14C]glucose (F) were assayed in each group. PFK-2 activity was denoted as the
relative value to that of the group without any treatment. Data shown are the means +− S.D. of triplicate samples from a representative experiment. The amount of FASN, ACLY, ACACA and androgen
receptor (AR) were measured by Western blot analyses in each group, using tubulin as an invariant control (G). EtOH, ethanol.
transient transfection in PC3 cells (Figure 6C) increased the PFK-
2 activity 3-fold (Figure 6A), which was accompanied by an in-
crease in glucose uptake (Figure 6B). In contrast with the overex-
pression experiment, knocking-down of the PFKFB2 expression
using siRNAs (Figures 6D and 6E) blocked the androgen-induced
increase in glucose uptake (Figure 6F). Accordingly, glucose-
dependent lipid synthesis was inhibited by knocking-down
PFKFB2 (Figure 6G); however, the increased levels of lipogenic
enzymes induced by androgen were not affected (Figure 6H).
These results indicate that an increase in glucose uptake mediated
by up-regulation of PFKFB2 is an important requirement for
androgen-dependent induction of lipid synthesis in LNCaP cells.
DISCUSSION
The androgen receptor has been implicated in proliferation and
progression of prostate tumours [5,28,29]. Androgen-induced
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Figure 6 PFKFB2 has a critical role in glucose uptake and lipid production in prostate cancer cells
PFK-2 activity (A) and glucose uptake (B) were measured in PC3 cells transfected with an empty vector or the pSG5-PFKFB2 expression vector. PFK-2 activity was denoted as the relative value to that
of mock-transfected cells. Data shown are the means +− S.D. of triplicate samples from a representative experiment. The expression of exogenous PFKFB2 was confirmed by Western blot analysis
using an antibody against the HA-tag. Tubulin was used as an invariant control (C). (D and E) The levels of PFKFB2 mRNA (D) and protein (E) were measured in LNCaP cells transfected with the
control or three independent PFKPB2 siRNAs (#1–#3) and then grown in the presence of R1881 for 72 h. Glucose uptake (F) and lipid synthesis from D-[1-14C]glucose (G) were determined in
LNCaP cells which were transfected with a control or the PFKPB2 siRNA #3 and then grown in the absence or presence of R1881 for 72 h as indicated. Values shown are the means +− S.D. of triplicate
samples from a representative experiment. The amount of FASN, ACLY and ACACA were measured by Western blot analyses in each group using tubulin as an invariant control (H). EtOH, ethanol.
lipogenesis is an important metabolic change necessary for
survival and proliferation of these tumours and the mechanisms
responsible for transcriptional activation of lipogenic enzyme
genes by the androgen receptor have been extensively studied
[1,3]. Glucose utilization has also been reported to be controlled
in an androgen-dependent manner in these tumours. In a clinical
study, androgen-ablation therapy suppressed glucose utilization
in prostate cancers [30] and most metastatic prostate cancers
that express high levels of androgen receptors demonstrate high
glucose uptake [31]. In general, glycolysis is known to be the
main carbon source for vigorous lipogenesis, but the studies
regarding how glycolysis is controlled by androgen in prostate
cancer cells are strictly limited. In the present study, we focused
on how androgen functions to induce glycolysis in LNCaP cells
and how this induced glycolysis is linked to changes in lipogenesis
required for cancer cell proliferation.
To address which glycolytic enzymes were transcriptionally
regulated by androgen in prostate cancer cells, we performed
a microarray analysis using total RNA isolated from LNCaP
cells treated with or without R1881. The transcripts for HK2 and
PFKFB2 among glycolytic enzymes were selectively elevated by
androgen treatment. Cancer cells display a high rate of glucose
uptake owing to elevated expression of glucose transporters and
increased HK activity [32]. Among the four mammalian HK
isoforms, it is proposed that the elevated HK activity in cancer
cells is mainly due to high expression of HK2 [25]. Even if prostate
cancer is known to have a relatively low glucose catabolic rate,
the high rate of de novo lipid synthesis induced by androgen
requires a carbon source from glycolysis. For this reason, the
increase in glycolysis by androgen should be accompanied with a
high rate of lipid synthesis. The present study revealed that HK2
and PFKFB2 are the major target genes for inducing glycolysis
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by androgen in LNCaP cells. HK2 is the principal isoform of
HKs in skeletal muscle, heart and adipose tissue [33], and its
activity is stimulated by exercise and β-adrenergic agonists,
which involve the cAMP/PKA signalling pathway [34,35]. The 5′
flanking region of the HK2 promoter is rich in putative response
elements, including six GC boxes, an E2F element, a CRE and
a CCAAT box [25,26]. Our results showed that the CRE in this
region plays a critical role in androgen-dependent activation of
HK2 in LNCaP (Figures 2B and 2C). In a previous report, we
have shown that R1881 enhanced the activity of PKA, which
plays an important role in proliferation [26a,36], and this increase
in PKA activity was correlated with the up-regulation of PKA-
Cβ2 by androgen treatment in LNCaP cells [26a]. We further
elucidated that the androgen-dependent induction of PKA-Cβ2
in the nucleus coincides with an increase in phosphorylation of
CREB, which binds to CRE and activates transcription of the
HK2 gene (Figure 2E). Taken together, it is strongly suggested
that the HK2 gene is regulated in an androgen-dependent manner
via up-regulation of the PKA signalling pathway in LNCaP
cells.
In addition to an increase in HK activity, persistent consumption
of glucose 6-phosphate into the glycolytic pathway is necessary
to achieve a high rate of glucose uptake. The fate of glucose 6-
phosphate to catabolic glycolysis is determined by the amount
of Fru-2,6-P2, whose synthesis and degradation are catalysed by
the bifunctional enzyme PFKFB. Mammals possess the distinct
isoforms of PFKFB encoded by four different genes (PFKFB1,
PFKFB2, PFKFB3 and PFKFB4) [12]. Rapidly proliferating
cancer cells produce markedly elevated levels of Fru-2,6-P2,
which is generally thought to be mediated by high expression of
PFKFB3 and PFKFB4 isoforms. However, in the present study, we
found that LNCaP cells uniquely express PFKFB2 which shows
a high ratio of kinase/phosphatase activity, as PFKFB3 does [15].
Expression of PFKFB2 was induced by the direct recruitment of
the ligand-activated androgen receptor to the PFKFB2 promoter
in LNCaP cells. The PFKFB2 promoter was activated by R1881 in
androgen-independent PC3 cells when the androgen receptor
was exogenously overexpressed (results not shown). Androgen-
dependent induction of PFKFB2 is assumed to induce glucose
uptake and glucose-dependent lipid synthesis in LNCaP cells,
because knocking-down PFKFB2 by siRNA severely impaired
both processes (Figures 6F and 6G). These results demonstrate
that the expression of PFKFB2 is directly regulated by the ligand-
activated androgen receptor and plays a key role in androgen-
induced glucose uptake and glucose-dependent lipid synthesis in
LNCaP cells.
In addition to the changes in the amount of PFKFB2,
the changes in kinase activity of PFKFB2 were addressed in the
present study, because the concentration of Fru-2,6-P2 can be
elevated only when its PFK-2 activity is activated [11]. The
regulation of PFK-2 activity is achieved by phosphorylation or
dephosphorylation of PFKFB2 at Ser466 and Ser483, mediated by
several kinases, such as calcium/calmodulin-dependent protein
kinase [27], PKA [37] or PI3K and Akt [19,20]. We have
revealed in the present study that the PFK-2 activity of PFKFB2
was regulated by the PI3K/Akt signalling pathway, which is
constitutively activated in LNCaP cells as a result of mutations of
PTEN, an important regulator of the PI3K/Akt signalling pathway
[38,39]. However, despite PKA activation by androgen, PKA did
not affect the phosphorylation status of PFKFB2. PFKFB4, which
is one of the isoforms expressed in LNCaP cells and known
to be overexpressed in various malignancies [16,40], was not
induced by androgen (results not shown). However, PFKFB4
might contribute little to glucose flux in prostate cancer cells,
considering that the inhibition of phosphorylation of PFKFB2 by
LY294002 inhibited androgen-induced PFK-2 activity to below
the basal level (Figure 5E).
In conclusion, the present study demonstrates that the
stimulation of HK2 and PFKFB2 by androgen induces high
glucose uptake and the activation of glucose utilization, resulting
in increased lipogenesis in prostate cancer.
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MATERIALS AND METHODS
Cell culture
LNCaP and PC3 cell lines were purchased from the A.T.C.C. and
were maintained in RPMI 1640 (Invitrogen) containing 10%
FBS (fetal bovine serum; Invitrogen), 100 units/ml penicillin
and 100 mg/ml streptomycin (Invitrogen). For the experiment
assessing the effect of androgen, cells were pre-incubated in
medium containing 5% CT-FBS (charcoal-treated FBS) instead
of FBS for 48 h and then further incubated in medium containing
1% CT-FBS in the presence or absence of 10 nM R1881 for 72 h.
CT-FBS was prepared by incubating FBS with dextran-coated
charcoal at 4◦C overnight and then removing the charcoal by
centrifugation [1].
Construction of recombinant plasmids
The 5′ flanking regions of the human HK2 and PFKFB2 gene
were amplified by PCR using the genomic DNA isolated from
LNCaP cells and the following primers: for the HK2 promoter
from − 2054 to +21 (arbitrarily numbered according to the first
base of the translated ATG annotated as +1), 5′-GTAATCCCAG-
CTATTTGGGACGCT-3′ and 5′-AAGCAGATGCGAGGCAA-
TTATCCTG-3′; for the PFKFB2 promoter from − 1949 to +92
(numbers deduced from transcription start site as +1, GenBank®
accession number NM_006212.2), 5′-TTAAATTGGGGCT-
TCCACACTACACC-3′ and 5′-CCTACGATCTCTCCTAAGA-
TCCCTCCC-3′. The PCR products were subcloned into the SmaI
site of pGL3-basic vector (Promega). The resulting plasmids
were designated as pHK2–Luc and pPFKFB2–Luc for HK2 and
PFKFB2 respectively. The CRE mutant construct of pHK2–
Luc and the ARE mutant construct of pPFKFB2–Luc were
generated using a QuikChange® Site-Directed Mutagenesis kit
(Stratagene) according to the manufacturer’s protocol. The
primers used for mutagenesis were: CRE, 5′-AATGGGC-
GTGCGCTCTTCACTGATCC-3′ and 5′-GGATCAGTGAAG-
AGCGCACGCCCATT-3′; ARE, 5′-AATCCATACTCATTGAA-
CGTTATCCAGCC-3′ and 5′-GGCTGGATAACGTTCAATGA-
GTATGGATT-3′. The expression vector for PKA-Cβ2 has been
described previously [1]. For the generation of the PFKFB2
expression vector, the full-length cDNA was amplified from
LNCaP cDNA using a primer set of 5′-GTCTGGGGCATC-
TTCCTCAGAACA-3′ and 5′-GCTAGTCGGCCCCTTCTTG-
CAT-3′, and was subcloned into the SmaI site of pSG5-HA-tagged
expression vector. The integrity of each construct was verified by
DNA sequencing.
Transient transfections and analyses of the promoter activity
PC3 cells (2 × 105 cells/well) were seeded into six-well plates
and were transfected with reporter constructs and expression
vectors (500 ng of DNA) using LipofectamineTM and Plus
reagent (Invitrogen) according to the manufacturer’s instructions.
pRL-SV40 (Promega) was co-transfected for standardization
of transfection efficiency. At 48 h after transfection, cells
were harvested and luciferase activities in 5 μl of cell lysates were
measured using the Dual-Luciferase Reporter Assay System®
(Promega) according to the manufacturer’s instructions. The
androgen-dependent transcriptional activation was assayed in
LNCaP cells as follows. LNCaP cells (3 × 106 cells) were seeded
in a 100-mm plate in medium containing 5% CT-FBS. At 48 h
after incubation, cells were transfected with 3 μg of HK2–Luc
or PFKFB2–Luc mixed with 6 ng of pRL-SV40 (Promega) as
described for PC3 cells. At 6 h after incubation, the medium
was replaced with fresh medium containing 5% CT-FBS. On
the next day, cells were trypsinized, transferred to each well of
a six-well plate, and further incubated in medium containing
1% CT-FBS with or without 10 nM R1881 for 72 h. After
incubation, luciferase activities were assayed as for PC3 cells
described above. All experiments were carried out in triplicate,
and luciferase activities were normalized to Renilla luciferase
activity to standardize transfection efficiency.
Quantitative RT-PCR
Total RNA was isolated from cultured cells using the TRIzol®
reagent (Invitrogen) according to the manufacturer’s protocol.
For quantitative RT-PCR, cDNA was synthesized from 4 μg
of total RNA using random hexamers and SuperScript reverse
transcriptase II® (Invitrogen) according to the manufacturer’s
protocol. The resulting cDNA was diluted with 80 μl of TE buffer
(10 mM Tris/HCl and 0.1 mM EDTA, pH 8.0) and 2 μl was
subsequently used for RT-PCR. The mixture in a volume of 10 μl,
containing cDNA and various sets of gene-specific primers, was
mixed with 10 μl of 2 × SYBR Green PCR Master Mix® (Applied
Biosystems) and then subjected to RT-PCR quantification using
the ABI PRISM 7300 Real-Time PCR System (Applied
Biosystems). The sequences of the primers used in RT-PCR were
1 Correspondence may be addressed to either of these authors (email swpark64@yuhs.ac or kyungsup59@yuhs.ac).
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as follows: PFKFB1, 5′-CCCTGGCCAACTTCATTCAG-3′ and
5′-TGTGACTGGTCCACACCTTCA-3′; PFKFB2, 5′-CCATG-
AAGATCCGCAAACAGT-3′ and 5′-TCCTCAGTGAGATAC-
GCCTTAACAT-3′; PFKFB3, 5′-CCGCTCATGAGACGCAATA-
GT-3′ and 5′-TTGATGCGAGGCTTTTTGGT-3′; PFKFB4, 5′-
TGACTATGTCAACCGCGACAGT-3′ and 5′-AGCACTCA-
ATGCGCCTCAT-3′; HK2, 5′-ATGGATGCCTAGATGACTTC-
CGCA-3′ and 5′-TAAGTGTTGCAGGATGGCTCGGA-3′;
KLK3, 5′-CAGGTATTTCAGGTCAGCCACA-3′ and 5′-AT-
GACCTTCACAGCATCCGTGA-3′; and GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase), 5′-CCCCTTCATTGA-
CCTTCAACTA-3′ and 5′-GAGTCCTTCCACGATACCAAAG-
3′. All reactions were performed in triplicate. The relative
amounts of RNA were calculated by using the comparative CT
method. GAPDH was used as an invariant control.
Western blot analyses
Cells were harvested and lysed in 2× SDS loading buffer,
then briefly sonicated. Lysates were cleared by centrifugation
at 13000 g for 10 min at 4◦C. Supernatants were collected
and protein concentrations were determined using the Bradford
assay (Bio-Rad). Aliquots of proteins (30 μg for each) were
separated by SDS/PAGE (8% gels) and transferred on to Protran®
nitrocellulose transfer membranes (Whatman). Membranes were
blocked in TBST (Tris-buffered saline containing 0.1% Tween
20) and 5% skimmed milk for 2 h, and incubated for 3 h or
overnight with primary antibody diluted in TBST. After washing
with TBST, the membrane was incubated with ImmunoPure
HRP (horseradish peroxidase)-conjugated goat anti-rabbit or anti-
mouse IgG antibody (Pierce) at room temperature for 20 min. The
immunoreactive bands were visualized with the SuperSignal West
Pico Chemiluminescent System® (Pierce). Antibodies used in the
present study were: HK2 (catalogue number SC-28889, Santa
Cruz Biotechnology), PFKFB2 (catalogue number SC-50953,
Santa Cruz Biotechnology), p-PFKFB2 Ser466 (catalogue number
SC-32966-R, Santa Cruz Biotechnology), p-PFKFB2 Ser483
(catalogue number SC-32967-R, Santa Cruz Biotechnology),
androgen receptor (catalogue number SC-815, Santa Cruz
Biotechnology) and HA-tag (catalogue number SC-7392, Santa
Cruz Biotechnology); CREB (catalogue number #9197, Cell
Signaling Technology) and phospho-CREB (catalogue number
#9191, Cell Signaling Technology); tubulin (catalogue number
CP-06, Calbiochem). The antibody against PKA-Cβ2 has been
described previously [1].
PKA activity
Cells treated as indicated were washed with PBS and lysed with
1 ml of lysis buffer (20 mM Mops, 50 mM 2-glycerolphosphate,
50 mM sodium fluoride, 1 mM sodiumvanadate, 5 mM EGTA,
2 mM EDTA, 1% Nonidet P40, 1 mM DTT, 1 mM benzamidin,
1 mM PMSF, 10 mg/ml leupeptin and 10 mg/ml aprotinin). The
cell lysates were collected 10 min after incubation, and cleared
supernatants were collected by centrifugation at 13400 g for
15 min. PKA activity in lysates was determined using the
StressXpress® PKA kinase assay kit (catalogue number EKS-
390A, Assay Design).
ChIP assay
ChIP assays were carried out using a ChIP assay kit (Upstate
Biotechnology) according to the manufacturer’s instructions.
Briefly, formaldehyde was added directly to cultured cells after
treatment with or without 10 nM R1881. After cross-linking,
cells were lysed with lysis buffer containing protease inhibitors,
nuclei were isolated, and the chromatin was sheared to an average
size in 250–500 bp long sections by sonication. The sheared
chromatin was pre-cleared with salmon sperm DNA/Protein
A–sepharose and then precipitated with the antibody against
the androgen receptor (catalogue number SC-815, Santa Cruz
Biotechnology). Rabbit IgG control was used to monitor non-
specific interactions. Immune complexes were adsorbed on
to salmon sperm DNA/Protein A–sepharose beads, washed
extensively, and eluted with elution buffer. After precipitation,
DNA was resuspended in water and PCR was performed
to amplify ARE regions of the PFKFB2 gene using the
following primers: ARE1, 5′-GGCAACTAGAGCACTCTGG-
GAGTTGT-3′ and 5′-CTTTTACAGTGGAGGTGAGTTTGCA-
CC-3′; ARE2, 5′-ATAGTTTCAAAGCCGACCAGAAAGC-3′
and 5′-TTGCCCATCCAATCTGGTAAGGAA-3′; ARE3, 5′-CC-
CTGACGTAACTAGAAGCACCACG-3′ and 5′-CACTAAAT-
TGGGATGCAACCTCAAGTG-3′; ARE4, 5′-CTGTCACTC-
CAGCAGAAAGAGGCAT-3′ and 5′-CAAGGGAACATGCC-
AAGGAGACAG-3′; and negative control, 5′-CCACCTTCAC-
CAAGGAAAGTGCTAAA-3′ and 5′-CAAGGCACACCCTC-
TAAAACTTAGCTTC-3′.
RNAi
Briefly, LNCaP cells (3 × 106 cells) were seeded in a 100-
mm plate in medium containing 5% CT-FBS. At 48 h after
incubation, cells were transfected with 18 μl of a 20 μM
three independent siRNA solution and 5 μl of LipofectamineTM
RNAiMAX were incubated in 500 μl of serum-free Opti-MEM
medium (Invitrogen) for 20 min and overlaid on to LNCaP cells
cultured in the wells of a six-well plate in 500 μl of serum-free
Opti-MEM medium. At 6 h after incubation, the medium was
replaced with fresh medium containing 5% CT-FBS. Cells were
transfected again in the same way on the next day. After overnight
incubation, cells were treated with or without 10 nM R1881 for
72 h in medium containing 1% CT-FBS. The mRNA and protein
levels of PFKFB2 were measured by quantitative RT-PCR and
Western blot analyses.
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